

Supplementary Table 1. Characteristics of Patients in the TFB and FIL Cohort before and after PS Matching

Characteristic	Before PS matching			After PS matching		
	TFB (n = 169)	FIL (n = 58)	SMD	TFB (n = 54)	FIL (n = 54)	SMD
Male sex	108 (63.9)	35 (60.3)	0.073	35 (64.8)	34 (63.0)	0.039
Age (yr)	40 ± 15	42 ± 15	0.153	42 ± 15	41 ± 14	0.074
Disease duration (yr)	6.7 ± 7.5	8.0 ± 8.0	0.163	9.2 ± 9.0	7.6 ± 7.7	0.181
Baseline corticosteroid use	35 (20.7)	9 (15.5)	0.135	7 (13.0)	9 (16.7)	0.104
Disease activity						
PMS	5.8 ± 1.7	4.9 ± 1.8	0.531	5.3 ± 1.6	5.1 ± 1.5	0.107
Albumin (g/L)	4.0 ± 2.2	4.0 ± 0.5	0.021	3.9 ± 0.4	3.9 ± 0.5	0.182
CRP (mg/L)	10.1 ± 15.5	5.0 ± 7.6	0.418	4.7 ± 6.6	5.3 ± 7.8	0.084

Values are presented as number (%) or mean ± standard deviation.

TFB, tofacitinib; FIL, filgotinib; PS, propensity score; SMD, standardized mean difference; PMS, partial Mayo score; CRP, C-reactive protein.